March 8, 2025

Enzalutamide 160 mg is a widely prescribed medication for the treatment of metastatic castration-resistant prostate cancer (mCRPC). As a potent androgen receptor inhibitor, Enzalutamide effectively reduces the influence of androgens on prostate cancer cells, slowing their growth and proliferation. However, like many potent cancer treatments, Enzalutamide’s impact extends beyond the tumor environment, potentially affecting the […]

Read More